ArticleBMC infectious diseases2025
Prognostic value of albumin-corrected anion gap in critically ill patients with sepsis-associated liver injury: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Albumin-corrected anion gap and 28-/90-day mortality in cirrhotic patients with invasive fungal infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Association between albumin-corrected anion gap and 28-day mortality in critically ill patients with pneumonia in the intensive care unit: evidence from the medical information mart for intensive care IV database.BMC pulmonary medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlbumin-corrected anion gap (ACAG) is closely associated with the prognosis of many critical illnesses. However, the prognostic value of ACAG in sepsis-associated liver injury (SALI) is poorly understood. We explored the association between ACAG and patient prognosis in individuals diagnosed with SALI.
methodsData from patients with SALI admitted to the intensive care unit (ICU) between 2008 and 2022 were retrospectively analyzed. ACAG was calculated based on the first measurement of the anion gap and albumin level within 24 h of admission. The optimal cutoff value for ACAG was established using R statistical software. Kaplan-Meier analysis was conducted to compare mortality risks between the two groups, while multivariable Cox proportional hazards regression models were employed to examine the association between ACAG and mortality risk in SALI patients. To assess a potential dose-response relationship, restricted cubic splines (RCS) were applied. Lastly, subgroup analyses were carried out to investigate the correlation between ACAG levels and prognosis across different patient populations.
resultsA total of 443 critically ill patients with SALI were included in the lower (n = 342) and higher ACAG (n = 101) groups based on ACAG levels. No statistically significant differences were observed between the two groups regarding age, sex, or ethnicity (P = 0.12, 0.84, and 0.85, respectively). However, patients in the higher ACAG group exhibited a greater propensity for developing respiratory failure. The rates of ICU, in-hospital, 14-day, 28-day, and 90-day mortality were significantly elevated in the higher ACAG group (all P < 0.001). Higher ACAG levels were significantly associated with an increased mortality risk at multiple time points (all P < 0.001). ACAG levels and mortality showed a significant linear relationship. The impact of ACAG on mortality risk remained consistent across subgroups defined by age, sex, hypertension, diabetes, and respiratory failure, with no significant interactions observed (all P for interaction > 0.05).
conclusionACAG serves as a significant independent predictor of mortality risk in patients with SALI. ACAG predicts both short-term mortality risk (such as ICU mortality) and long-term mortality risk (such as 90-day mortality). ACAG may serve as a valuable tool for prognostic assessment in patients with SALI with broad applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.